Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MISSION-1: Tofacitinib in Down Syndrome
NCT07598643Phase 2Recruiting
- Sponsor
- University of Colorado Denver
- Start
- May 2026
- Primary completion
- Aug 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tofacitinib oral solution in Down syndrome, sponsored by University of Colorado Denver. Started May 2026; status: recruiting.
02
Drugs
tofacitinib oral solution
03
Conditions
Down syndrome
Beyond the preview
Go deeper on NCT07598643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598643.